Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.32 |
| ▸ | PDE4A | P27815 | 5/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465860 | 1.00 | DPP4 (0.32) | DPP4DPP7PDE4DPDE4APDE4B | |
| SCHEMBL3465890 | 1.00 | DPP4 (0.32) | DPP4DPP7PDE4DPDE4APDE4B | |
| SCHEMBL3465856 | 1.00 | DPP4 (0.32) | DPP4DPP7PDE4DPDE4APDE4B | |
| SCHEMBL3465889 | 1.00 | DPP4 (0.32) | DPP4DPP7PDE4DPDE4APDE4B | |
| SCHEMBL4640207 | 0.84 | CHRNB2 (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4641123 | 0.84 | CHRNB2 (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4640210 | 0.84 | CHRNB2 (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4641127 | 0.84 | CHRNB2 (0.37) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4640214 | 0.84 | PDE4D (0.33) | DPP4DPP7PDE4DPDE4APDE4B | |
| SCHEMBL4641185 | 0.84 | PDE4D (0.33) | DPP4DPP7PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-1948654-B1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| EP-1948654-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007031558-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | DPP4 2562/4885DPP7 1660/4885PDE4D 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.